RxDoctor Payments Data

Dawn Whelchel, MD

Internal Medicine · Marshall, TXNPI 1194726299

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 51 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$312
  • Astellas Pharma US Inc$100
  • Amgen$90
  • Pfizer$68
  • Merck$63
  • Lilly USA, LLC$50
  • plus $336 from 12 others

What the payments were for

  • Food & beverage$89988%
  • Education$12012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,019 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$120,086
Medicare patients
189
Services billed
1,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$100,544
EliquisApixaban90$61,740
JardianceEmpagliflozin50$38,258
XareltoRivaroxaban20$25,843
MyrbetriqMirabegron50$19,320
TradjentaLinagliptin12$16,936
JanuviaSitagliptin Phosphate23$16,836
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,579
FarxigaDapagliflozin Propanediol20$16,361
KerendiaFinerenone23$14,661
BelsomraSuvorexant24$13,695
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$13,402
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$13,258
LinzessLinaclotide18$13,055
RytaryCarbidopa/Levodopa24$11,815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$61,74090 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$36$33,55850 claims
MerckJanuvia, Belsomra$63$30,53147 claims
GSKTrelegy Ellipta, Anoro Ellipta$50$29,83746 claims
Astellas Pharma US IncMyrbetriq$100$19,32050 claims
BayerKerendia$312$14,66123 claims
AbbVieLinzess$42$13,05518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Marshall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →